ORXO.F Stock Overview
A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.08 |
| 52 Week High | SEK 1.95 |
| 52 Week Low | SEK 1.08 |
| Beta | 0.60 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -30.32% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORXO.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -5.3% | -1.2% |
| 1Y | -30.3% | 8.7% | 30.4% |
Return vs Industry: ORXO.F underperformed the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: ORXO.F underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| ORXO.F volatility | |
|---|---|
| ORXO.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ORXO.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ORXO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 113 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
| ORXO.F fundamental statistics | |
|---|---|
| Market cap | US$29.68m |
| Earnings (TTM) | -US$9.64m |
| Revenue (TTM) | US$54.51m |
0.5x
P/S Ratio-3.1x
P/E RatioIs ORXO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORXO.F income statement (TTM) | |
|---|---|
| Revenue | SEK 595.70m |
| Cost of Revenue | SEK 69.80m |
| Gross Profit | SEK 525.90m |
| Other Expenses | SEK 631.20m |
| Earnings | -SEK 105.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | -3.05 |
| Gross Margin | 88.28% |
| Net Profit Margin | -17.68% |
| Debt/Equity Ratio | -1,688.6% |
How did ORXO.F perform over the long term?
See historical performance and comparison